Risk of diabetes and the impact on preexisting diabetes in patients with lymphoma treated with steroid-containing immunochemotherapy.
Journal
Blood advances
ISSN: 2473-9537
Titre abrégé: Blood Adv
Pays: United States
ID NLM: 101698425
Informations de publication
Date de publication:
09 08 2022
09 08 2022
Historique:
received:
21
12
2021
accepted:
29
05
2022
pubmed:
10
6
2022
medline:
4
8
2022
entrez:
9
6
2022
Statut:
ppublish
Résumé
First-line treatments for lymphomas often include high doses of prednisolone, but the risks of new-onset diabetes mellitus (DM) or worsening of preexisting DM following treatment with cyclic high dose corticosteroids is unknown. This cohort study matched non-Hodgkin lymphoma (NHL) patients treated with steroid-containing immunochemotherapy (ie, R-CHOP[-like] and R-CVP) between 2002 and 2015 to individuals from the Danish population to investigate the risks of new-onset DM. For patients with preexisting DM, the risks of insulin dependency and anthracycline-associated cardiovascular diseases (CVDs) were assessed. In total, 5672 NHL patients and 28 360 matched comparators were included. Time-varying incidence rate ratios (IRRs) showed increased risk of DM in the first year after treatment compared with matched comparators, with the highest IRR being 2.7. The absolute risks were higher among patients in the first 2 years, but the difference was clinically insignificant. NHL patients with preexisting DM had increased risks of insulin prescriptions with 0.5-, 5-, and 10-year cumulative risk differences of insulin treatment of 15.3, 11.8, and 6.0 percentage units as compared with the DM comparators. In a landmark analysis at 1 year, DM patients with lymphoma had decreased risks of insulin dependency compared with comparators. Time-varying IRRs showed a higher CVD risk for NHL patients with DM as compared with comparators in the first year after treatment. NHL patients treated with steroid-containing immunochemotherapy regimens have a clinically insignificant increased risk of DM in the first year following treatment, and patients with preexisting DM have a temporary increased risk of insulin prescriptions and CVD.
Identifiants
pubmed: 35679481
pii: 485509
doi: 10.1182/bloodadvances.2021006859
pmc: PMC9636321
doi:
Substances chimiques
Insulins
0
Prednisone
VB0R961HZT
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
4427-4435Informations de copyright
© 2022 by The American Society of Hematology. Licensed under Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0), permitting only noncommercial, nonderivative use with attribution. All other rights reserved.
Références
Clin Cancer Res. 2002 Jun;8(6):1681-94
pubmed: 12060604
Scand J Public Health. 2011 Jul;39(7 Suppl):72-4
pubmed: 21775357
J Clin Oncol. 2015 Aug 10;33(23):2516-22
pubmed: 26124482
Blood Cancer J. 2021 Jan 7;11(1):9
pubmed: 33414443
J Am Geriatr Soc. 1956 Jul;4(7):627-41
pubmed: 13331730
J Clin Oncol. 2002 Feb 15;20(4):1017-25
pubmed: 11844825
Ann Nutr Metab. 2014;65(4):324-32
pubmed: 25402408
Support Care Cancer. 2014 May;22(5):1385-90
pubmed: 24362844
Clin Epidemiol. 2015 Nov 17;7:449-90
pubmed: 26604824
Scand J Public Health. 2011 Jul;39(7 Suppl):38-41
pubmed: 21775349
Lifetime Data Anal. 2013 Jul;19(3):279-96
pubmed: 23329123
Am J Hematol. 2016 Nov;91(11):1096-1101
pubmed: 27465588
J Transl Int Med. 2016 Apr 1;4(1):46-51
pubmed: 28191518
Cancer Res. 1973 Nov;33(11):3024-8
pubmed: 4748450
Ann Oncol. 2017 Dec 1;28(12):3109
pubmed: 28327933
J Endocrinol. 2011 Oct;211(1):17-25
pubmed: 21602312
PLoS One. 2016 Jun 23;11(6):e0157999
pubmed: 27336800
Diabetes Metab Res Rev. 2014 Feb;30(2):96-102
pubmed: 24123849
J Clin Oncol. 2019 Nov 1;37(31):2815-2824
pubmed: 31339826
Lancet Oncol. 2011 May;12(5):460-8
pubmed: 21482186
Eur J Cancer. 2018 Aug;99:86-96
pubmed: 29935491
PLoS One. 2011;6(12):e27326
pubmed: 22205924
J Clin Oncol. 2006 Jul 1;24(19):3121-7
pubmed: 16754935
Cancer. 2005 May 15;103(10):2171-80
pubmed: 15812823
Int J Med Sci. 2014 Sep 06;11(11):1185-200
pubmed: 25249787
J Adolesc Health. 2004 Apr;34(4):330-8
pubmed: 15041003
N Engl J Med. 2002 Jan 24;346(4):235-42
pubmed: 11807147
Oncologist. 2000;5(3):238-49
pubmed: 10884502
Med Care. 2005 Nov;43(11):1130-9
pubmed: 16224307
Br J Haematol. 2016 May;173(3):487-91
pubmed: 26223361
Acta Oncol. 2017 Apr;56(4):618-627
pubmed: 28084890
J Clin Oncol. 2005 Dec 1;23(34):8884-93
pubmed: 16314649
Br J Haematol. 2018 Dec;183(5):717-726
pubmed: 30406945
Lancet Oncol. 2006 May;7(5):379-91
pubmed: 16648042
Support Care Cancer. 2007 Jun;15(6):621-630
pubmed: 17205274
J Am Med Assoc. 1950 Dec 16;144(16):1349-53
pubmed: 14778746
Stat Methods Med Res. 2010 Feb;19(1):71-99
pubmed: 19654170
Ann Oncol. 2018 Aug 1;29(8):1822-1827
pubmed: 29897404
Am J Health Behav. 2003 May-Jun;27(3):246-56
pubmed: 12751621
Scand J Public Health. 2011 Jul;39(7 Suppl):30-3
pubmed: 21775347
Am J Clin Oncol. 2011 Jun;34(3):292-6
pubmed: 20622641
N Engl J Med. 1993 Apr 8;328(14):1002-6
pubmed: 7680764
Endocrinol Metab (Seoul). 2017 Jun;32(2):180-189
pubmed: 28555464
Ann Oncol. 2015 Sep;26 Suppl 5:v116-25
pubmed: 26314773
J Clin Oncol. 2017 Mar;35(7):778-784
pubmed: 28095160
Leuk Lymphoma. 2018 Aug;59(8):1871-1877
pubmed: 29252084